Loading
AGCT1531 is testing two ways to spare people with germ cell tumours from long-term harm: watching low-risk patients after surgery and giving chemotherapy only if the tumour returns, and swapping cisplatin for carboplatin, which is kinder to hearing, in standard-risk disease; it is still recruiting.
AGCT1531 is a Children's Oncology Group phase 3 study run with adult cooperative groups for malignant extracranial germ cell tumours from birth to age 50. Low-risk patients (stage I) enter active surveillance after surgery with chemotherapy reserved for relapse. Standard-risk patients are randomised to bleomycin, etoposide and carboplatin or bleomycin, etoposide and cisplatin, with paediatric and adult dosing schedules; the primary endpoints are event-free and overall survival at two years, and ototoxicity is a central secondary endpoint.
The registry gives an estimated enrolment of 1,780 with a primary completion date of June 2027 and no results. The corpus's childhood germ cell tumour page cites the AGCT1531 stratum for surveillance with chemotherapy only at relapse.
Shares Germ cell tumours of childhood and adolescence (extracranial and CNS), Childhood cancers (all types), Children's Oncology Group (COG), Etoposide and the tag soc-trials.
Shares Bleomycin, Childhood cancers (all types), Children's Oncology Group (COG), Etoposide and the tag soc-trials.
Shares Bleomycin, Testicular germ cell tumours, Etoposide, Cisplatin and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Carboplatin and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Cisplatin and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Carboplatin and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Cisplatin and the tag soc-trials.
Shares Childhood cancers (all types), Cisplatin, Carboplatin, Cytotoxic chemotherapy and the tag soc-trials.